Superior Biomarker quantification, through robust assay performance and high sensitivity.

Chimera Biotec is highly experienced at providing ultra sensitive biomarker sample testing for all phases of drug development - from discovery to preclinical and clinical studies. We have a long track record of supporting trials targeting a wide range of disease areas including oncology and neurology (CNS), as well as inflammatory, infectious, and metabolic diseases. Virtually any matrix can be explored utilizing the Imperacer® platform's outstanding ability to maintain extreme sensitivity despite high sample dilution.

Literature list

Ultra Sensitive Cytokine Quantificationrequest reprint
Imperacer® (Immuno-PCR) Method Development and Validation for Ultra Sensitive Quantification of Interferon Gamma in Human Plasma to Support Clinical Phase I of a Cancer Vaccine Candidaterequest reprint
Highly Sensitive Cytokine Quantification using Imperacer®, an Immuno-PCR based Ligand-Binding Assay Systemrequest reprint
Development and Validation of an Ultra Sensitive Imperacer (Immuno-PCR) Method for Quantification of Human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)request reprint
Clinical Biomarker Quantification: Novel Tools for Pharmacodynamic Applicationsrequest reprint
Challenges in Developing a Sensitive PD Assay–From Tool Selection to Technologies Evaluationrequest reprint
Detecting Antigens by Quantitative Immuno-PCRrequest reprint
An Ultra Sensitive Immuno-qPCR Assay for Quantitation of Intact Pegylated Interferon Beta-1a in Human Serumrequest reprint
Feasibility of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosisrequest reprint
Imperacer® pTau Microsampling Bioanalytical Approach Supports Transgenic Mouse CSF Measurementrequest reprint
Ultrasensitive Multiparameter Biomarker Quantification in Microsampling Support request reprint
Ultrasensitive Biomarker Quantification in Dried Blood Spot Samplesrequest reprint